Loading...
•
Jun 30, 2021
Edwards Lifesciences Q2 2021 Earnings Report
Edwards Lifesciences reported strong second-quarter results, driven by a rebound in sales and growth across all product groups.
Key Takeaways
Edwards Lifesciences reported a strong second quarter with sales up 49% to $1.4 billion and underlying sales growth of 44%. TAVR sales exceeded expectations, growing 52%. The company raised its full-year sales guidance to $5.2 to $5.4 billion and adjusted EPS guidance to the high end of the previous $2.07 to $2.27 range.
Sales rebounded and grew 49 percent to $1.4 billion; underlying sales grew 44 percent
TAVR sales exceeded expectations and grew 52 percent; underlying sales grew 48 percent
EPS was $0.78; adjusted EPS was $0.64
Continued progress on five pivotal trials in TMTT
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
The company now expects full year 2021 sales of $5.2 to $5.4 billion versus previous guidance of $4.9 to $5.3 billion. The company is raising full year 2021 adjusted earnings per share guidance to the high end of the previous $2.07 to $2.27 range. For the third quarter of 2021, the company projects sales to be between $1.29 and $1.37 billion, and adjusted EPS of $0.50 to $0.56.
Revenue & Expenses
Visualization of income flow from segment revenue to net income